AOLS Scores 52-week High on Latest Test Results
Many companies in the pharmaceutical industry experience dynamic movements up and down the charts when test results are released to the public. Aeolus Pharmaceuticals Inc. (OTCBB: AOLS) scored an A-plus today with their news about AEOL 10113, demonstrating potential to accelerate recovery of bone marrow stem cells following cancer radiation therapy. Shares were trading well above the 52-week high of 91 cents to $1.10 (up 38 percent) on volume of over 372 thousand shares. In a press release, Aeolus announced the presentation of data by researchers at Loma Linda University Medical Center, National Jewish Medical and Research Center and Duke…